SEARCH

SEARCH BY CITATION

References

  • 1
    Edwards KM, Decker MD. Pertussis vaccine. In: Plotkin S, Orenstein WA, Offit PA, eds, Vaccines, 4th edn. Philadelphia: Saunders, 2004; 471528.
  • 2
    Baron S, Njamkepo E, Grimprel E et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998; 17: 412418.
  • 3
    Bonmarin I, Levy-Bruhl D, Baron S, Guiso N, Njamkepo E, Caro V. Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill 2007; 12: 12011226.
  • 4
    Wendelboe AM, Njamkepo E, Bourillon A et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26: 293299.
  • 5
    Anonymous. Avis du conseil supérieur d’hygiène publique de France du 13 mars 1998. Bulletin Epidémiologique Hebdomadaire 1998; 15: 6162.
  • 6
    Caro V, Njamkepo E, van Amersfoorth SC et al. Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect 2005; 7: 976982.
  • 7
    Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 2001; 39: 43964403.
  • 8
    Bouchez V, Caro V, Levillain E, Guigon G, Guiso N. Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS ONE 2008; 3: e2437.
  • 9
    Heikkinen E, Kallonen T, Saarinen L et al. Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS ONE 2007; 2: e904.
  • 10
    Kallonen T, Grondahl-Yli-Hannuksela K, Elomaa A et al. Differences in the genomic content of Bordetella pertussis isolates before and after introduction of pertussis vaccines in four European countries. Infect Genet Evol 2011; 11: 20342042.
  • 11
    King AJ, van Gorkom T, Pennings JL et al. Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics 2008; 9: 311.
  • 12
    Mooi FR, He Q, Guiso N. Phylogeny, evolution and epidemiology of bordetellae. In: Locht FC, ed. Bordetella: molecular microbiology, Norfolk, United Kingdom: Publischer Horizon Bioscience, 2007: 1745.
  • 13
    Kurova N, Njamkepo E, Brun D, Tseneva G, Guiso N. Monitoring of Bordetella isolates circulating in Saint Petersburg, Russia between 2001 and 2009. Res Microbiol 2010; 161: 810815.
  • 14
    Guiso N. Bordetella pertussis and pertussis vaccines. Clin Infect Dis 2009; 49: 15651569.
  • 15
    Khelef N, Danve B, Quentin-Millet MJ, Guiso N. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species. Infect Immun 1993; 61: 486490.
  • 16
    Liese JG, Renner C, Stojanov S, Belohradsky BH. Clinical and epidemiological picture of B. pertussis and B. parapertussis infections after introduction of acellular pertussis vaccines. Arch Dis Child 2003; 88: 684687.
  • 17
    Long GH, Karanikas AT, Harvill ET, Read AF, Hudson PJ. Acellular pertussis vaccination facilitates Bordetella parapertussis infection in a rodent model of bordetellosis. Proc Biol Sci 2010; 277: 20172025.
  • 18
    Heininger U, Stehr K, Christenson P, Cherry JD. Evidence of efficacy of the lederle/takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clin Infect Dis 1999; 28: 602604.
  • 19
    Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine 2009; 27: 60346041.
  • 20
    Bouchez V, Brun D, Dore G, Njamkepo E, Guiso N. Bordetella parapertussis isolates not expressing pertactin circulating in France. Clin Microbiol Infect 2011; 17: 675682.
  • 21
    Njamkepo E, Cantinelli T, Guigon G, Guiso N. Genomic analysis and comparison of Bordetella pertussis isolates circulating in low and high vaccine coverage areas. Microbes Infect 2008; 10: 15821586.
  • 22
    Mooi FR, Hallander H, Wirsing von Konig CH, Hoet B, Guiso N. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur J Clin Microbiol Infect Dis 2000; 19: 174181.
  • 23
    Mooi FR, van Loo IH, van Gent M et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 2009; 15: 12061213.
  • 24
    Dalet K, Weber C, Guillemot L, Njamkepo E, Guiso N. Characterization of adenylate cyclase-hemolysin gene duplication in a Bordetella pertussis isolate. Infect Immun 2004; 72: 48744877.
  • 25
    Stefanelli P, Fazio C, Fedele G, Spensieri F, Ausiello CM, Mastrantonio P. A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells. New Microbiol 2009; 32: 159166.
  • 26
    Parkhill J, Sebaihia M, Preston A et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 2003; 35: 3240.
  • 27
    Khelef N, Zychlinsky A, Guiso N. Bordetella pertussis induces apoptosis in macrophages: role of adenylate cyclase-hemolysin. Infect Immun 1993; 61: 40644071.
  • 28
    Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman DA, Mooi FR. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog 2005; 1: e45.
  • 29
    Otsuka N, Han HJ, Toyoizumi-Ajisaka H et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS One 2012; 7: e31985.